Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Cyclophosphamide Drug Market Share, Size, Growth, Analysis, Forecast: By Route of Administration: Oral, Parenteral; By Dose: High Dose, Low Dose; By Disease: Cancer Disease, Autoimmune Disease, AL Amyloidosis, Others; By Distribution Channel: Hospital Based Pharmacies, Others; Regional Analysis; Supplier Landscape; 2023-2031
Global Cyclophosphamide Drug Market Outlook
The growth of the global Cyclophosphamide drug market is expected to grow with a CAGR of 2.2% during the forecast period of 2023-2031, driven by the growing incidences of cancer. The market is expected to reach a value of USD 806 million by 2031.
Cyclophosphamide Drug Market: Insights
These drugs are classified as alkylating agents. It slows or stops the growth of cancer cells in the body when used in the treatment of cancer. It suppresses the body's immune system when used to treat nephrotic syndrome. A kidney condition, known as nephrotic syndrome, makes the body excrete excessive amounts of protein in urine. The clusters of tiny blood capillaries in the kidneys that filter waste and extra water from the blood are typically damaged by nephrotic syndrome.
Cyclophosphamide, solely or in combination with other drugs, is used for the treatment of various cancers, like lymphoma, myeloma, and leukaemia. It is also used in the therapy of retinoblastoma, neuroblastoma, ovarian cancer, and breast cancer. Metabolites is the main way through which the drug is excreted from the body.
Neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhoea are the adverse effects that are most frequently reported.
According to the Cyclophosphamide drug market research report, the market can be categorised into the following segments:
Market Breakup by Route of Administration
- Oral
- Parenteral
Market by Dose
- High Dose
- Low Dose
Market by Disease
- Oncology
- Autoimmune Diseases
- AL Amyloidosis
- Others
Market by Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Market Scenario
The Cyclophosphamide drug is on the list of essential medicines by WHO. The demand for the drug is increasing with increased cases of cancer among the population in the future. More combinations are under development and trial for the treatment of wide spectrum of diseases.
It is used as an alkylating drug to stop and slow the growth of tumours by directly damaging DNA and cross-linking guanine bases in DNA double-helix strands. It is used to treat several cancers, including lung cancer, breast cancer, eye cancer, blood cell cancer, white bone, and bone marrow cancer. This drug is used to treat a particular form of kidney illness in children with nephrotic syndrome. Product consumption will increase as healthcare industry grows. Therefore, throughout the anticipated period, the growth of the market would be driven by the rising demand.
The Cyclophosphamide drug market in Asia Pacific is expected to increase gradually. The rapid rise in the healthcare industry can be attributed to the increase. Furthermore, an increasing number of disorders, such as blood cell cancer and lung cancer, have increased the product in the nephrotic syndrome and AL amyloidosis, which will drive market expansion in North America. Increased use of Cyclophosphamide drugs in hospitals and clinics is driving the growth in Europe.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the global Cyclophosphamide drug market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Baxter Laboratories Ltd.
- Novartis AG
- Himka Pharmaceuticals Plc.
- Amneal Pharmaceuticals LLC
- NorthStar Rx LLC
- Aurobindo Pharma Ltd.
- CSC Pharmaceutical International
- Jiangsu Hengrui Medicine Co Ltd
- Nodus Oncology
- Abbive, Inc.
- Theravance Biopharm, Inc.
- Sanofi S.A.
- Roxane Laboratories Pvt Ltd
- LGM Pharma Llc
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Route of Administration |
|
| Breakup by Dose |
|
| Breakup by Disease |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Cyclophosphamide Drug Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Cyclophosphamide Drug Market
6.1 Global Cyclophosphamide Drug Market Overview
6.2 Global Cyclophosphamide Drug Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Cyclophosphamide Drug Market Historical Value (2016-2022)
6.2.1.2 Global Cyclophosphamide Drug Market Forecast Value (2023-2031)
6.3 Global Cyclophosphamide Drug Market by Route of Administration
6.3.1 Market Overview
6.3.1.1 Oral
6.3.1.2 Parenteral
6.4 Global Cyclophosphamide Drug Market by Dose
6.4.1 Market Overview
6.4.1.1 High Dose
6.4.1.2 Low Dose
6.5 Global Cyclophosphamide Drug Market by Disease
6.5.1 Market Overview
6.5.1.1 Cancer Disease
6.5.1.2 Autoimmune Disease
6.5.1.3 AL Amyloidosis
6.5.1.4 Others
6.6 Global Cyclophosphamide Drug Market by Distribution Channel
6.6.1 Market Overview
6.6.1.1 Hospital Based Pharmacies
6.6.1.2 Online Pharmacies
6.6.1.3 Retail Pharmacies
6.7 Global Cyclophosphamide Drug Market by Region
6.7.1 Market Overview
6.7.1.1 North America
6.7.1.1.1 Historical Trend (2016-2022)
6.7.1.1.2 Forecast Trend (2023-2031)
6.7.1.2 Europe
6.7.1.2.1 Historical Trend (2016-2022)
6.7.1.2.2 Forecast Trend (2023-2031)
6.7.1.3 Asia Pacific
6.7.1.3.1 Historical Trend (2016-2022)
6.7.1.3.2 Forecast Trend (2023-2031)
6.7.1.4 Latin America
6.7.1.4.1 Historical Trend (2016-2022)
6.7.1.4.2 Forecast Trend (2023-2031)
6.7.1.5 Middle East and Africa
6.7.1.5.1 Historical Trend (2016-2022)
6.7.1.5.2 Forecast Trend (2023-2031)
7 North America Cyclophosphamide Drug Market
7.1 United States of America
7.1.1 Historical Trend (2016-2022)
7.1.2 Forecast Trend (2023-2031)
7.2 Canada
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
8 Europe Cyclophosphamide Drug Market
8.1 United Kingdom
8.1.1 Historical Trend (2016-2022)
8.1.2 Forecast Trend (2023-2031)
8.2 Germany
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3 France
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4 Italy
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
9 Asia Pacific Cyclophosphamide Drug Market
9.1 China
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2 Japan
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 India
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4 ASEAN
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5 Australia
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
10 Latin America Cyclophosphamide Drug Market
10.1 Brazil
10.1.1 Historical Trend (2016-2022)
10.1.2 Forecast Trend (2023-2031)
10.2 Argentina
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Mexico
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
11 Middle East and Africa Cyclophosphamide Drug Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2016-2022)
11.1.2 Forecast Trend (2023-2031)
11.2 United Arab Emirates
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Nigeria
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 South Africa
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Investment Scenarios
12.5 Regulatory Framework
12.5.1 Regulatory Overview
12.5.1.1 US FDA
12.5.1.2 EU EMA
12.5.1.3 INDIA CDSCO
12.5.1.4 JAPAN PMDA
12.5.1.5 Others
13 Challenges and Unmet Need
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Rate
13.3 Awareness and Prevention Gaps
14 Global Cyclophosphamide Drug Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Drug Adoption Parameters
14.4 Porter’s Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Baxter Laboratories Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievement
15.1.4 Merger and Acquisitions
15.1.5 Certifications
15.2 Novartis AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievement
15.2.4 Merger and Acquisitions
15.2.5 Certifications
15.3 Hikma Pharmaceuticals Plc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievement
15.3.4 Merger and Acquisitions
15.3.5 Certifications
15.4 Amneal Pharmaceuticals Llc
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievement
15.4.4 Merger and Acquisitions
15.4.5 Certifications
15.5 NorthStar Rx Llc
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievement
15.5.4 Merger and Acquisitions
15.5.5 Certifications
15.6 Aurobindo Pharma Ltd.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievement
15.6.4 Merger and Acquisitions
15.6.5 Certifications
15.7 CSC Pharmaceuticals International
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievement
15.7.4 Merger and Acquisitions
15.7.5 Certifications
15.8 Jiangsu Hengrui Medicine Co Ltd
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievement
15.8.4 Merger and Acquisitions
15.8.5 Certifications
15.9 Nodus Oncology
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievement
15.9.4 Merger and Acquisitions
15.9.5 Certifications
15.10 Abbive, Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievement
15.10.4 Merger and Acquisitions
15.10.5 Certifications
15.11 Theravance Biopharma, Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievement
15.11.4 Merger and Acquisitions
15.11.5 Certifications
15.12 Sanofi S.A.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievement
15.12.4 Merger and Acquisitions
15.12.5 Certifications
15.13 Roxane Laboratories Pvt Ltd
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievement
15.13.4 Merger and Acquisitions
15.13.5 Certifications
15.14 LGM Pharma Llc
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievement
15.14.4 Merger and Acquisitions
15.14.5 Certifications
16 Recommendations and Discussion
17 Pricing Models and Strategies (Additional Insight)
17.1 Cost Model
17.1.1 Manufacturing Cost Analysis
17.1.2 Procurement Cost Analysis
17.2 Pricing Strategies
17.2.1 Competitor Pricing Analysis
17.2.2 Key Assessment of Product Attributes
17.2.3 Pricing Benchmark
18 Global Cyclophosphamide Drug Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customizable as per client requirements
Key Questions Answered in the Report
The market value was about USD 666 million in 2022, driven by the rising cases of cancer.
The market is likely to grow at a CAGR of 2.2% during the forecast period of 2023-2031 to attain a value of USD 806 million by 2031.
Cancers of the ovaries, breast, blood and lymphatic systems, and nerves are all treated with Cyclophosphamide drug (mainly in children). Retinoblastoma, a bone marrow malignancy that primarily affects youngsters, multiple myeloma, and mycosis fungoides, are all treated with Cyclophosphamide drug (tumours on the skin).
The major regions in the global market are North America, Latin America, Asia Pacific, Europe, and Middle East and Africa.
The drug causes various side effects including nausea, vomiting, and appetite loss.
It does not work immediately and usually takes about 6 weeks to start working.
The average percentage of objective responses is 43%. This includes a 38% response rate for individuals who have already received treatment and a 29% response rate for patients who had previously failed to respond to the drug.
In some ANCA-associated vasculitis (AAV) patients, mycophenolate mofetil (MMF) may be a safe and effective substitute for the drug.
The key players in this market include Baxter Laboratories Ltd., Novartis AG, Himka Pharmaceuticals Plc., Amneal Pharmaceuticals LLC, NorthStar Rx LLC, Aurobindo Pharma Ltd., CSC Pharmaceutical International, Jiangsu Hengrui Medicine Co Ltd, Nodus Oncology, Abbive, Inc., Theravance Biopharm, Inc., Sanofi S.A., Roxane Laboratories Pvt Ltd, and LGM Pharma Llc, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$2499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$4999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$6499-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$7999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER